arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Dermata Therapeutics, Inc.

DRMA
$0.78 ▼ -0.05 (-6.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Dermata Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -68.3% ↘
FCF / Share $-0.60 ↗
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-1.85M
↑ +19.8% —
FCF / Share Free cash flow per share
$-0.60
↑ +6.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters